Calm vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Calm is a leading mental wellness app offering sleep, meditation, and relaxation content with enterprise health benefits programs serving over 100 million downloads.
About
Calm is a digital mental health company founded in 2012 by Michael Acton Smith and Alex Tew that has grown into one of the most downloaded and highest-grossing health apps globally. The platform offers guided meditations, sleep stories narrated by celebrities, breathing exercises, and relaxing music designed to reduce stress, improve sleep quality, and support overall mental wellness. Calm has exceeded 100 million downloads and reached a $2B valuation with backing from TPG, making it one of the most valuable standalone consumer wellness applications. The company has expanded into enterprise with Calm Business, providing employee mental health and wellbeing benefits to thousands of organizations. Calm has invested heavily in content production, partnering with prominent voices including LeBron James, Matthew McConaughey, and Harry Styles for exclusive audio content. The company also offers Calm Kids with age-appropriate mindfulness content for children. While positioned primarily as a consumer wellness tool rather than a clinical platform, Calm's scale and brand recognition have made it a leading solution for companies seeking accessible, low-friction mental wellness benefits for large employee populations.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.